Praveen Jagwani, CEO of UTI International, discusses the rise of Indian pharma in the wake of the U.S. Biosecure Act dampening competition from China.
.
Praveen Jagwani, CEO of UTI International, discusses the rise of Indian pharma in the wake of the U.S. Biosecure Act dampening competition from China.
Praveen Jagwani, CEO of UTI International, discusses the rise of Indian pharma in the wake of the U.S. Biosecure Act dampening competition from China.
.
